Prevention is safer, faster and cheaper than cure.
Peezy Midstream takes the guesswork out of diagnosis and treatment.
“ The NHS spent £434m treating 184,000 patients for UTI related unplanned admission in 2013/14. In the USA, 46% of urine retests are not reimbursed. How much is careless urine collection really costing healthcare providers and patients? ”
CEO, Forte Medical
Urine is one of the most important carriers of cancer biomarkers, bacteria, protein, glucose and more, all of which can raise the alarm to serious illness. If left undiagnosed these conditions can become far more difficult and costly to treat.
Yet there is no gold standard for urine collection anywhere in the world, leaving patients vulnerable to failed diagnosis and failed treatment:
- 50% AMR incidences have a urinary source
- 47% Gram-negative blood infections caused by urinary tract infection
- 22% Average unreliable urine specimens (USA and UK)
Forte Medical has developed world-first technology that delivers super-accurate urine specimens and right-first-time preventative urine-based medicine. Peezy Midstream reduces specimen contamination to just 1-2.5%, delivering diagnostic integrity, targeted treatment and huge financial savings.
We are now developing The Specimen Collection, a portfolio of devices designed to help with identification of early stage cancers including prostate, testicular, cervical, bladder, kidney and more. Smart digital solutions are planned for each product.
Peezy Midstream is MHRA registered, FDA listed and patented.